JP Morgan Initiates Novavax At Overweight

Analysts at JP Morgan initiated coverage on shares of Novavax

with a Overweight rating. The target price for Novavax is set to $7. Novavax shares have jumped 37.25% over the past 52 weeks, while the S&P 500 index has gained 18.69% in the same period. Novavax's shares rose 2.19% to close at $4.20 yesterday.